ZBH vs. EW, STE, ALGN, SNN, MSA, ENOV, ESTA, CDRE, AVNS, and ZJYL
Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Edwards Lifesciences (EW), STERIS (STE), Align Technology (ALGN), Smith & Nephew (SNN), MSA Safety (MSA), Enovis (ENOV), Establishment Labs (ESTA), Cadre (CDRE), Avanos Medical (AVNS), and Jin Medical International (ZJYL). These companies are all part of the "surgical appliances & supplies" industry.
Edwards Lifesciences (NYSE:EW) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
Edwards Lifesciences currently has a consensus target price of $95.06, suggesting a potential upside of 9.31%. Zimmer Biomet has a consensus target price of $133.75, suggesting a potential upside of 16.15%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Edwards Lifesciences.
Edwards Lifesciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Edwards Lifesciences received 422 more outperform votes than Zimmer Biomet when rated by MarketBeat users. Likewise, 71.85% of users gave Edwards Lifesciences an outperform vote while only 68.09% of users gave Zimmer Biomet an outperform vote.
In the previous week, Edwards Lifesciences had 1 more articles in the media than Zimmer Biomet. MarketBeat recorded 20 mentions for Edwards Lifesciences and 19 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.85 beat Edwards Lifesciences' score of 0.47 indicating that Edwards Lifesciences is being referred to more favorably in the media.
79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Edwards Lifesciences has a net margin of 23.01% compared to Edwards Lifesciences' net margin of 12.93%. Zimmer Biomet's return on equity of 22.86% beat Edwards Lifesciences' return on equity.
Edwards Lifesciences has higher earnings, but lower revenue than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Summary
Edwards Lifesciences beats Zimmer Biomet on 14 of the 18 factors compared between the two stocks.
Get Zimmer Biomet News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zimmer Biomet Competitors List
Related Companies and Tools
